Royalty Pharma plc

RPRXNASDAQHealthcareBiotechnology

$60.96- (-)1Y +61.09%

As of Oct 16, 2026 close

Market cap: $33.21B
P/E (TTM): 40.75
Forward P/E: 51.12
Dividend yield: 1.55%
52-week range: $35.79$64.38
Volume (live): -
Avg. volume (3M): 3.27M

Royalty Pharma plc (RPRX) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Royalty Pharma plc stock.

Analyst Consensus Rating

Investment consensus from 8 professional research analysts

Consensus Rating

Buy

Based on 8 unique analysts

(12 total ratings in last 90 days)

Medium Confidence∞:1 Buy/Sell

Average Price Target

$66.00

+8.27% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest RPRX Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 12, 2026	Geoff Meacham	Citi	Maintains	Buy	$70.00
Oct 9, 2026	Jason Gerberry	BofA Securities	Maintains	Buy	$63.00
Oct 7, 2026	Terence Flynn	Morgan Stanley	Maintains	Buy	$67.00
Sep 29, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Hold	-
Sep 24, 2026	Jason Gerberry	BofA Securities	Maintains	Buy	$63.00
Sep 9, 2026	Geoff Meacham	Citi	Maintains	Buy	$70.00
Sep 8, 2026	Michael Nedelcovych	TD Cowen	Reiterates	Buy	$65.00 → $68.00 +3.00 (+4.6%)
Sep 8, 2026	Ashwani Verma	UBS	Reiterates	Buy	$66.00
Aug 11, 2026	Chris Schott	JP Morgan	Maintains	Buy	$62.00
Aug 10, 2026	Chris Schott	JP Morgan	Maintains	Buy	$62.00
Aug 6, 2026	Asad Haider	Goldman Sachs	Maintains	Buy	$59.00 → $66.00 +7.00 (+11.9%)
Aug 6, 2026	Terence Flynn	Morgan Stanley	Reiterates	Buy	$64.00 → $65.00 +1.00 (+1.6%)

Geoff Meacham

Citi

BuyMaintains

$70.00

Oct 12

Jason Gerberry

BofA Securities

BuyMaintains

$63.00

Oct 9

Terence Flynn

Morgan Stanley

BuyMaintains

$67.00

Oct 7

Zacks Equity Research

HoldInitiates Coverage

Sep 29

Jason Gerberry

BofA Securities

BuyMaintains

$63.00

Sep 24

Geoff Meacham

Citi

BuyMaintains

$70.00

Sep 9

Michael Nedelcovych

TD Cowen

BuyReiterates

$65.00 → $68.00

Sep 8

Ashwani Verma

UBS

BuyReiterates

$66.00

Sep 8

Chris Schott

JP Morgan

BuyMaintains

$62.00

Aug 11

Chris Schott

JP Morgan

BuyMaintains

$62.00

Aug 10

Asad Haider

Goldman Sachs

BuyMaintains

$59.00 → $66.00

Aug 6

Terence Flynn

Morgan Stanley

BuyReiterates

$64.00 → $65.00

Aug 6

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 12, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for RPRX?

The analyst consensus rating for RPRX is Buy, based on the latest ratings from 8 analysts over the last 90 days.

What is the average price target for RPRX?

The average 12-month price target for RPRX is $66.00, representing an upside of 8.3% from the Oct 16, 2026 close of $60.96.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.